ReviewInternational journal of pharmaceutics: X2025
Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control.
Review in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges.International journal of molecular sciences · 2026Pooled it
- Design rules for externally triggered drug uncaging under optical and radiolytic regimes.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2026Review
- Understanding DMG: current treatment options and prospective solutions using nanoparticles.Drug delivery and translational research · 2026Review
- Article
- Nanoceria-curcumin nanoplatform enhances radiotherapy efficacy in triple-negative breast cancer via microenvironmental redox modulation and TNF-α-NF-κB/inflammatory program suppression.Materials today. Bio · 2026Article
- Schisandrin B Exerts Radiosensitizing Effects on Breast Cancer via Dual Mechanisms of Cell Cycle/DNA Repair and Gut Microbiota-Immune Axis Modulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer affects millions of individuals annually, with radiotherapy playing a crucial role in the treatment of over 70% of cases. Nevertheless, the effectiveness of radiotherapy is frequently limited by tumor radioresistance and the associated toxicity to normal tissues. Radiosensitizers enhance tumor sensitivity to ionizing radiation, optimizing doses and reducing damage. This review evaluates diverse radiosensitizers, including natural compounds (curcumin, resveratrol), chemotherapeutics (cisplatin, doxorubicin), and high-Z nanoparticles (gold, hafnium), which amplify DNA damage and ROS production. Advanced nanocarriers-carbon-, lipid-, and polymer-based-improve targeted delivery, specificity, and bioavailability. Various molecular mechanisms involving proteins such as p53, PARP1, miRNAs (miR-21, miR-155), and siRNAs are discussed in relation to their roles in modulating cell cycle progression, apoptosis, and gene expression to overcome resistance. Radioprotectors like antioxidants and amifostine safeguard normal tissues. Ongoing trials with hafnium oxide and cisplatin regimens show promise. Key findings highlight nanotechnology's role in enhancing radiosensitization via dose enhancement factors and synergistic therapies. Implications include personalized treatments tailored to tumor biology, the reduction of radioresistance through precision medicine and data-driven strategies, and ultimately, the improvement of radiotherapy efficacy and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.